The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index; 6 of the 116 sources its claims cite were checked for support.
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Open accessAbstract
In past two decades poly lactic-co-glycolic acid (PLGA) has been among the most attractive polymeric candidates used to fabricate devices for drug delivery and tissue engineering applications. PLGA is biocompatible and biodegradable, exhibits a wide range of erosion times, has tunable mechanical properties and most importantly, is a FDA approved polymer. In particular, PLGA has been extensively studied for the development of devices for controlled delivery of small molecule drugs, proteins and other macromolecules in commercial use and in research. This manuscript describes the various fabrication techniques for these devices and the factors affecting their degradation and drug release.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review surveys poly lactic-co-glycolic acid (PLGA) as a biodegradable controlled drug delivery carrier, covering its properties, copolymer systems, fabrication methods, release behavior, degradation factors, toxicology, and modeling. It concludes that PLGA is versatile and FDA-approved, with degradation and release tunable through composition, molecular weight, crystallinity, device geometry, and drug characteristics.
Key findings
- PLGA is biocompatible, biodegradable, FDA-approved, and can be processed into nanospheres, microspheres, and millimeter-sized implants; it degrades by ester hydrolysis into lactic and glycolic acids, which are eliminated through normal metabolic routes or the kidney.
- Degradation rate depends strongly on lactide-to-glycolide ratio: 50:50 PLGA degrades fastest, followed by 65:35, 75:25, and 85:15; higher glycolic acid content increases degradation, while higher molecular weight generally slows it. PLGA copolymers have a glass transition temperature above 37 °C and are glassy at physiological temperature.
- Drug release is often biphasic, with an initial burst followed by slower diffusion and erosion; release is influenced by drug type and load, matrix surface-area-to-volume ratio, pH, crystallinity, and possibly enzymes, though reports on crystallinity and enzymatic degradation conflict.
- Fabrication approaches include single and double emulsion, coacervation, spray drying, nanoprecipitation, salting out, solvent casting and compression molding, extrusion, supercritical CO₂ foaming, and multifunctional micro/nanoparticles; PLGA/PEG block copolymers can form thermogels but may reduce encapsulation efficiency.
Methods
- Narrative review of prior literature; no experimental study, systematic search strategy, or primary data collection is described.
- Synthesizes published work on PLGA physicochemical properties, pharmacokinetics and biodistribution, copolymer architectures, fabrication techniques, drug release behavior, degradation factors, toxicology, and mathematical modeling.
- Includes equations for diffusion-controlled release, first-order molecular weight loss, and particle-size distributions such as Weibull or Rosin–Rammler models.
Limitations
- The paper states that mechanisms of PLGA degradation and release are not clearly understood, that crystallinity effects are conflicting, that the role of enzymes is unresolved, and that in vivo and in vitro degradation rates often do not correlate well.
- It notes that nanoscale PLGA may have distinct biodistribution and toxicological profiles, and that local tissue reactions at application sites can occur, though generally mild.
- Evident from the text: as a narrative review, it lacks systematic search criteria, quality appraisal, and quantitative synthesis, so conclusions rest on selected cited studies rather than a formal evidence assessment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 of 116 cited sources checked · 3 supported · 0 flagged · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The main advantage of this approach over micro/nanospheres is related to the ability to manage adverse events, since implants retain a degree of reversibility which is not available in depot mechanisms [12,59].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.3. Implant Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [12] Siegel, 2006, Effect of drug type on the degradation rate of PLGA matrices, Eur. J. Pharm. Biopharm. source
- Supportedcites [59] Rabin, 2008, In vitro and in vivo demonstration of risperidone implants in mice, Schizophr. Res. source
The Introduction describes depot injections as irreversible and says the implants bypass that limitation. The Discussion (Potential Advantages) says implants can be removed if a problem arises, supporting the claimed advantage for managing adverse events. The paper describes fabrication by solvent casting in Materials and Methods; it does not separately compare the implants with micro- or nanospheres. (LLM, conf=0.88)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“However, the high rate clearance of micro/nanoparticles by the body’s reticuloendothelial system (RES) and the difficultyfor such particles to penetrate many tissue types may limit their use to the vascular space [69–71].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.4. Miscellaneous Systems
What the sources say
- Not checked — no full text of the sourcecites [69] Xu, 2010, Synthesizing and binding dual-mode poly (lactic-co-glycolic acid) (PLGA) nanobubbles for cancer targeting and imaging, Biomaterials source
- Could not verifycites [70] Zhang, 2010, Multifunctional microbubbles for image-guided antivascular endothelial growth factor therapy, J. Biomed. Opt. sourceExperimental — accuracy not yet measured
The Abstract discusses micro- and nanobubbles for imaging and intraocular drug delivery, but does not address clearance by the reticuloendothelial system or difficulty penetrating tissue. Searches for those mechanisms and for confinement to the vascular space found no relevant passage in our copy. Page numbers were not provided. (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [71] Sun, 2008, Multifunctional poly(D,L-lactide-co-glycolide)/ montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer, Biomaterials source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Such multifunctional particles can also be formulated from a component material to reduce side effects of the encapsulated drug [70].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.4. Miscellaneous Systems
What the sources say
- Partly supportedcites [70] Zhang, 2010, Multifunctional microbubbles for image-guided antivascular endothelial growth factor therapy, J. Biomed. Opt. sourceExperimental — accuracy not yet measured
The paper describes multifunctional PLGA microbubbles made from a biocompatible, biodegradable material for targeted delivery (Abstract; page unavailable). It does not report reduced drug side effects; the encapsulated substance in this study was Texas Red dye, while the anti-VEGF drug Avastin was conjugated to the microbubble surface. (LLM, conf=0.87)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“PLGA are a family of FDA-approved biodegradable polymers that are physically strong and highly biocompatible and have been extensively studied as delivery vehicles for drugs, proteins and various other macromolecules such as DNA, RNA and peptides [1–3].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Bouissou, 2006, The influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release, Pharm. Res. source
- Not checked — no full text of the sourcecites [2] Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials source
- Not checked — no full text of the sourcecites [3] Ruhe, 2003, rhBMP-2 release from injectable poly (DL-lactic-co-glycolic acid)/calcium-phosphate cement composites, J. Bone Jt. Surg. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“PLGA are a family of FDA-approved biodegradable polymers that are physically strong and highly biocompatible and have been extensively studied as delivery vehicles for drugs, proteins and various other macromolecules such as DNA, RNA and peptides [1–3].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Bouissou, 2006, The influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release, Pharm. Res. source
- Not checked — no full text of the sourcecites [2] Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials source
- Not checked — no full text of the sourcecites [3] Ruhe, 2003, rhBMP-2 release from injectable poly (DL-lactic-co-glycolic acid)/calcium-phosphate cement composites, J. Bone Jt. Surg. source
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“PLGA are a family of FDA-approved biodegradable polymers that are physically strong and highly biocompatible and have been extensively studied as delivery vehicles for drugs, proteins and various other macromolecules such as DNA, RNA and peptides [1–3].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Bouissou, 2006, The influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release, Pharm. Res. source
- Not checked — no full text of the sourcecites [2] Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials source
- Not checked — no full text of the sourcecites [3] Ruhe, 2003, rhBMP-2 release from injectable poly (DL-lactic-co-glycolic acid)/calcium-phosphate cement composites, J. Bone Jt. Surg. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Biodistribution and pharmacokinetics of PLGA follows a non-linear and dose-dependent profile [14].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
What the sources say
- Not checked — no full text of the sourcecites [14] Yang, 2001, Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method, Biomaterials source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Better release kinetics from formulations of diblock copolymers have been demonstrated in comparison to PLGA alone.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.2. Copolymers of PLGA
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Using these techniques, processing parameters such as orientation of jets, material flow rates, and rate of solvent extraction can be controlled to create uniform and well-centered double-walled microspheres exhibiting a controllable shell thickness [52].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [52] Berkland, 2004, Uniform double-walled polymer microspheres of controllable shell thickness, J. Control. Release source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“PLGA physical properties themselves have been shown to depend upon multiple factors, including the initial molecular weight, the ratio of lactide to glycolide, the size of the device, exposure to water (surface shape) and storage temperature [11].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
What the sources say
- Not checked — no full text of the sourcecites [11] Houchin, 2009, Physical properties of PLGA films during polymer degradation, J. Appl. Polym. Sci. source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 22
- It may state two separate claims as one. 27
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Solvent casting is a method to fabricate a macroscopic millimeter size formulation which can be implanted or inserted for long term medication [59].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.3. Implant Preparation Techniques
What the sources say
- Partly supportedcites [59] Rabin, 2008, In vitro and in vivo demonstration of risperidone implants in mice, Schizophr. Res. sourceExperimental — accuracy not yet measured
The Materials and Methods (page not given) describe solvent casting risperidone and polymer, then molding or extruding the film into implantable pellets or rods. The Introduction and Conclusions describe long-term drug delivery, but the passages do not specify millimeter-sized dimensions; the demonstrated use is a risperidone implant in mice, not a general formulation for long-term medication. (LLM, conf=0.81)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“PLGA/PEG block copolymers have been processed as diblock (PLGA-PEG) [18,19] or triblock molecules with both ABA (PLGA-PEG-PLGA) [20] and BAB (PEG-PLGA-PEG) [21] types.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.2. Copolymers of PLGA
What the sources say
- Supportedcites [18] Cheng, 2007, Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery, Biomaterials source
The citation to this paper is attached to the diblock (PLGA-PEG) portion of the sentence, not the triblock types. Sections 2.2.1 and 3.1 describe synthesizing PLGA-b-PEG by conjugating a PLGA block with a PEG block. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [19] Li, 2001, PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats, J. Control. Release source
- Not checked — no full text of the sourcecites [20] Ghahremankhani, 2007, PLGA-PEG-PLGA tri-block copolymers as an in-situ gel forming system for calcitonin delivery, Polym. Bull. source
- Not checked — no full text of the sourcecites [21] Jeong, 2000, In situ gelation of PEGPLGAPEG triblock copolymer aqueous solutions and degradation thereof, J. Biomed. Mater. Res. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Unlike solvent-casting, extrusion is a continuous process of drawing polymer-drug mixture through a die to create implants of fixed cross-sectional profile without any use of solvent.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.3. Implant Preparation Techniques
What the sources say
- Supportedcites [61] Wang, 2010, A rapid method for creating drug implants: Translating laboratory-based methods into a scalable manufacturing process, J. Biomed. Mater. Res. Part B Appl. Biomater. source
The Discussion describes extrusion, in contrast to solvent-casting, as a continuous, solvent-free process for making drug implants. Materials and Methods > Extrusion describes feeding a polymer–drug mixture through an extruder die to produce rods, consistent with the claimed fixed cross-sectional profile. (LLM, conf=0.90)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“PLGA are a family of FDA-approved biodegradable polymers that are physically strong and highly biocompatible and have been extensively studied as delivery vehicles for drugs, proteins and various other macromolecules such as DNA, RNA and peptides [1–3].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Bouissou, 2006, The influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release, Pharm. Res. source
- Not checked — no full text of the sourcecites [2] Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials source
- Not checked — no full text of the sourcecites [3] Ruhe, 2003, rhBMP-2 release from injectable poly (DL-lactic-co-glycolic acid)/calcium-phosphate cement composites, J. Bone Jt. Surg. source
Strength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“PLGA are a family of FDA-approved biodegradable polymers that are physically strong and highly biocompatible and have been extensively studied as delivery vehicles for drugs, proteins and various other macromolecules such as DNA, RNA and peptides [1–3].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Bouissou, 2006, The influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release, Pharm. Res. source
- Not checked — no full text of the sourcecites [2] Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials source
- Not checked — no full text of the sourcecites [3] Ruhe, 2003, rhBMP-2 release from injectable poly (DL-lactic-co-glycolic acid)/calcium-phosphate cement composites, J. Bone Jt. Surg. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Salting out is another method in which a water-in-oil emulsion is first formed containing polymer, solvent (usually non chlorinated like acetone), salt (e.g., magnesium acetate tetrahydrate) and stabilizer. Water is then added to the solution until the volume is sufficient to diffuse acetone into the water, resulting in nanoparticle formulations [55–58].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.2. Nanoparticle Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [55] Lamprecht, 2000, Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique, Int. J. Pharm. source
- Not checked — no full text of the sourcecites [56] Murakami, 1999, Preparation of poly(D,L-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method, Int. J. Pharm. source
- Not checked — no full text of the sourcecites [57] Konan, 2003, Preparation and characterization of sterile sub-200 nm meso-tetra(4-hydroxylphenyl)porphyrin-loaded nanoparticles for photodynamic therapy, Eur. J. Pharm. Biopharm. source
- Not checked — no full text of the sourcecites [58] Kwon, 2001, Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method, Colloids Surf. A Physicochem. Eng. Asp. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The main disadvantage of this process is the adhesion of the microparticles to the inner walls of the spray-dryer.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“A modification on this procedure called the double or multiple emulsion technique has become the favored protocol for encapsulating hydrophilic compounds and proteins [37].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.2. Nanoparticle Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [37] Mao, 2007, Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres, Int. J. Pharm. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“It is soluble in wide range of common solvents including chlorinated solvents, tetrahydofuran, acetone or ethyl acetate [7,10].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
What the sources say
- Not checked — no full text of the sourcecites [7] Uhrich, 1999, Polymeric systems for controlled drug release, Chem. Rev. source
- Not checked — no full text of the sourcecites [10] Wu, 2001, Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers. Part II: Biodegradation, J. Biomater. Sci. Polym. Ed. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Additionally, microfluidic devices can incorporate the use of electrostatic forces to control the size and shape of particles for increased tuning of release characteristics [53].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [53] Loscertales, 2002, Micro/Nano encapsulation via electrified coaxial liquid jets, Science source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Nanoparticles can also be synthesized by nanoprecipitation methods. Polymer and drug are dissolved in acetone and added to an aqueous solution containing Pluronic F68. The acetone is evaporated at appropriate temperatures and reduced pressures leaving behind the polymer encapsulated nanoparticles with drug [54].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.2. Nanoparticle Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [54] Hans, 2002, Biodegradable nanoparticles for drug delivery and targeting, Curr. Opin. Solid State Mater. Sci. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Drug delivery of peptides and proteins may also require parenteral formulations to avoid degradation in the digestive tract and first pass metabolism, while the short circulating half-lives of peptides and proteins contribute to the need for parenteral formulations that will reduce dosing frequency.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Presence of methyl side groups in PLA makes it more hydrophobic than PGA and hence lactide rich PLGA copolymers are less hydrophilic, absorb less water and subsequently degrade more slowly.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Alternatively, spray drying is very rapid, convenient and has very few processing parameters, making it suitable for industrial scalable processing.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The copolymer is usually a free flowing solution at low temperature and can form a high viscosity gel at body temperature.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.2. Copolymers of PLGA
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mechanical strength, swelling behavior, capacity to undergo hydrolysis and subsequently biodegradation rate of the polymer are directly influenced by the degree of crystallinity of the PLGA, which is further dependent on the type and molar ratio of the individual monomer components in the copolymer chain.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Emulsion techniques require precise control of processing parameters for higher encapsulation efficiency, and phase separation techniques tend to produce agglomerated particles and also require removal of large quantities of the organic phase from the microspheres. This makes the process difficult for mass production.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Degree of crystallinity and melting point of the polymers are directly related to the molecular weight of the polymer.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Biocompatibility is clearly important, although it is important to note that biocompatibility is not an intrinsic property of a material, but depends on the biological environment and the tolerability that exists with respect to specific drug-polymer-tissue interactions [9].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers
What the sources say
- Not checked — no full text of the sourcecites [9] Anderson, 1997, Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv. Drug Deliv. Rev. source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Recently, coaxial capillary flows have become a preferable technique to produce monodispersed micro/nanoparticles with either simple or core-shell structure because of their precise control on mean particle size [50,51].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [50] Barrero, 2007, Micro- and nanoparticles via capillary flows, Annu. Rev. Fluid Mech. source
- Not checked — no full text of the sourcecites [51] Freitas, 2005, Microencapsulation by solvent extraction/evaporation: Reviewing the state of the art of microsphere preparation process technology, J. Control. Release source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Drugs formulated in such polymeric devices are released either by diffusion through the polymer barrier, or by erosion of the polymer material, or by a combination of both diffusion and erosion mechanisms.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As a rule, higher content of PGA leads to quicker rates of degradation with an exception of 50:50 ratio of PLA/PGA, which exhibits the fastest degradation, with higher PGA content leading to increased degradation interval below 50%.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The degradation of the PLGA carriers is quick on the initial stage (around 30%) and slows eventually to be cleared by respiration in the lung [16].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
What the sources say
- Not checked — no full text of the sourcecites [16] Bazile, 1992, Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats, Biomaterials source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“This method is known to encapsulate all kinds of drugs/peptides/proteins into microparticles without significant loss in their biological activity.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Crystalline PGA, when co-polymerized with PLA, reduces the degree of crystallinity of PLGA and as a result increase the rate of hydration and hydrolysis.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Triblock copolymers of both ABA and BAB type can act as a thermogel with an A-block covalently coupled with a B-block via ester link.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.2. Copolymers of PLGA
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The Tg (glass transition temperature) of the PLGA copolymers are reported to be above the physiological temperature of 37 °C and hence are glassy in nature, thus exhibiting fairly rigid chain structure.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.1. Poly Lactic-co-Glycolic Acid (PLGA)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The nature of solvent used, temperature of the solvent evaporation and feed rate affects the morphology of the microspheres.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Water-in-oil-in-water emulsion methods are best suited to encapsulate water-soluble drugs like peptides, proteins, and vaccines, unlike single emulsion methods which is ideal for water-insoluble drugs like steroids.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.1. Microparticle Preparation Techniques
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“This layer of PEG acts as a barrier and reduces the interactions with foreign molecules by steric and hydrated repulsion, giving enhanced shelf stability [22].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 2. Biodegradable Polymers > 2.2. Copolymers of PLGA
What the sources say
- Not checked — no full text of the sourcecites [22] Tobio, 1998, Stealth PLA-PEG nanoparticles as protein carriers for nasal administration, Pharm. Res. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The role of enzymes in any PLGA biodegradation is unclear. Most literature indicate that the PLGA biodegradation does not involve any enzymatic activity and is purely through hydrolysis. However, some investigators have suggested an enzymatic role in PLGA breakdown based upon the difference in the in vitro and in vivo degradation rates.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 4. Drug Release Behavior > 4.1. Biphasic Release
What the sources say
- Not checked — no full text of the sourcecites [80] Alexis, 2005, Factors affecting the degradation and drug-release mechanism of poly (lactic acid) and poly [(lactic acid)-co-(glycolic acid)], Polym. Int. source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Denatured species are therapeutically inactive and can cause unpredictable side effects, such as immunogenicity or other toxicity.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.3. Implant Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [60] Widmer, 1998, Manufacture of porous biodegradable polymer conduits by an extrusion process for guided tissue regeneration, Biomaterials source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“At the moment, there are conflicting reports on the effect of crystallinity on the degradation rate [80].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 4. Drug Release Behavior > 4.2. Factors Affecting Degradation
What the sources say
- Not checked — no full text of the sourcecites [80] Alexis, 2005, Factors affecting the degradation and drug-release mechanism of poly (lactic acid) and poly [(lactic acid)-co-(glycolic acid)], Polym. Int. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The PLGA polymer biodegrades into lactic and glycolic acids. Lactic acid enters the tricarboxylic acid cycle and is metabolized and subsequently eliminated from the body as carbon dioxide and water [75]. Glycolic acid is either excreted unchanged in the kidney or it enters the tricarboxylic acid cycle and is eventually eliminated as carbon dioxide and water.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 4. Drug Release Behavior > 4.1. Biphasic Release
What the sources say
- Not checked — no full text of the sourcecites [75] Crotts, 1998, Protein delivery from poly (lactic-co-glycolic acid) biodegradable microspheres: Release kinetics and stability issues, J. Microencapsul. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“After such pressurization and rapid depressurization sequence, the thermodynamic instability of CO2 molecules leads to their clustering inside the liquid polymer. As CO2 leaves, the emulsion results in a porous polymer structure [66,67].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.4. Miscellaneous Systems
What the sources say
- Not checked — no full text of the sourcecites [66] Koushik, 2004, Preparation of large porous Deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process, Pharm. Res. source
- Not checked — no full text of the sourcecites [67] Davies, 2008, Applications of supercritical CO2 in the fabrication of polymer systems for drug delivery and tissue engineering, Adv. Drug Deliv. Rev. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“PLGA 50:50 (PLA/PGA) exhibited a faster degradation than PLGA 65:35 due to preferential degradation of glycolic acid proportion assigned by higher hydrophilicity. Subsequently PLGA 65:35 shows faster degradation than PLGA 75:25 and PLGA 75:25 than PLGA 85:15 [79].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 4. Drug Release Behavior > 4.2. Factors Affecting Degradation
What the sources say
- Not checked — no full text of the sourcecites [79] Park, 1995, Degradation of poly(lactic-co-glycolic acid) microspheres: Effect of copolymer composition, Biomaterials source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Third, solvent-casting and compression molding are not continuous processes, which may increase batch-to-batch variation in the composition of implants as well as cost of manufacturing [60].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 3. Fabrication Techniques for PLGA Carriers > 3.3. Implant Preparation Techniques
What the sources say
- Not checked — no full text of the sourcecites [60] Widmer, 1998, Manufacture of porous biodegradable polymer conduits by an extrusion process for guided tissue regeneration, Biomaterials source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“The ratio of surface area to volume has shown to be a significant factor for degradation of large devices. Higher surface area ratio leads to higher degradation of the matrix.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 4. Drug Release Behavior > 4.2. Factors Affecting Degradation
What the sources say
- Not checked — no full text of the sourcecites [82] Schliecker, 2003, Hydrolytic degradation of poly(lactide-co-glycolide) films: Effect of oligomers on degradation rate and crystallinity, Int. J. Pharm. source
- Not checked — no full text of the sourcecites [86] Witt, 2001, Morphological characterization of microspheres, films and implants prepared from poly(lactide-co-glycolide) and ABA triblock copolymers: Is the erosion controlled by degradation, swelling or diffusion?, Eur. J. Pharm. Biopharm. source
- Not checked — no full text of the sourcecites [87] Grizzi, 1995, Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence, Biomaterials source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In general, the PLGA degradation and the drug release rate can be accelerated by greater hydrophilicity, increase in chemical interactions among the hydrolytic groups, less crystallinity and larger volume to surface ratio of the device.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 5. Conclusions and Future Prospects
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
In the paper
“The first stage of drug release is through random scission of the polymer without any polymer weight loss and is mainly through diffusion, while the second stage is characterized by the onset of weight loss.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 4. Drug Release Behavior > 4.4. Modeling of PLGA Drug Release Profiles
What the sources say
- Not checked — no full text of the sourcecites [96] Berchane, 2007, Effect of mean diameter and polydispersity of PLG microspheres on drug release: Experiment and theory, Int. J. Pharm. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Several studies suggest that nanoparticles of any material may create specific biodistribution and toxicological profiles [95].”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 4. Drug Release Behavior > 4.3. Toxicology
What the sources say
- Not checked — no full text of the sourcecites [95] Olivier, 1999, Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity, Pharm. Res. source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, multiple studies demonstrate that PLGA can easily be formulated into the drug carrying devices at all scales, i.e., as nanospheres, as microspheres and even as millimeter sized implants, can encapsulate a wide range of drugs, peptides or proteins and can be delivered over different periods of time with diverse routes of delivery.”
§ Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier > 5. Conclusions and Future Prospects
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
A pulsated drug release profile is sometimes preferred over continuous drug presence because continuous presence may lead to receptor downregulation or tolerance development.
“A pulsated drug release profile is sometimes preferred over the continuous presence of the drug, which may lead to downregulation of receptors or the development of tolerance.”
The paper relies on this without support.
Large macroscopic formulations act as a drug reservoir that can be delivered over a longer interval.
“Large size, macroscopic formulations act as a reservoir for drug that can be delivered over a longer interval.”
The paper relies on this without support.
All microparticle preparation techniques described earlier can be employed for manufacturing PLGA nanoparticles by adjusting processing parameters.
“All the above described microparticle techniques can be employed for manufacturing PLGA nanoparticles (nanospheres and nanocapsules) by adjusting the processing parameters.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It allows for adjustable degradation rates and hydrophilicity by changing the PGA:PLA ratio, where higher PLA concentrations increase hydrophobicity, degradation time, and consequently incorporated drug release.[ 201 ]”
From Unraveling and Harnessing the Immune Response at the Cell–Biomaterial Interface for Tissue Engineering Purposes (2024) · cites this paper as [201]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Examples of polyesters for solubilizing hydrophobic drugs are PCL, PDLLA and PLGA [106–108].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [106]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“and the material mineralization can be expedited in the presence of immobilized growth factors [91–95].”
From Polydopamine-Assisted Surface Modification for Bone Biosubstitutes (2016) · cites this paper as [91]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Upon immobilization of BMP, the property of osteoblast cells responsive to polymeric materials can be remarkably improved”
From Polydopamine-Assisted Surface Modification for Bone Biosubstitutes (2016) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“Drug release occurs via bulk degradation of the polymer and drug diffusion 12 and can be modified by altering the hydrophobicity of the monomer, polymer chain length and particle size 13 .”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Opposite device-size trends for degradation
MajorThe conclusion says a larger volume-to-surface ratio accelerates degradation, while Section 4.2.5 says a higher surface-area-to-volume ratio increases degradation. These ratios move in opposite directions.
“In general, the PLGA degradation and the drug release rate can be accelerated by greater hydrophilicity, increase in chemical interactions among the hydrolytic groups, less crystallinity and larger volume to surface ratio of the device.”
“The ratio of surface area to volume has shown to be a significant factor for degradation of large devices. Higher surface area ratio leads to higher degradation of the matrix.”
PDLA and PLLA are described as physically alike and structurally unlike
MinorThe paper calls their physicochemical properties nearly the same, then describes PLLA as highly crystalline and PDLA as completely amorphous. Those are substantially different physical properties.
“The physicochemical properties of optically active PDLA and PLLA are nearly the same.”
“In general, the polymer PLA can be made in highly crystalline form (PLLA) or completely amorphous (PDLA) due to disordered polymer chains.”
Opposite device-size ratios are said to accelerate degradation
MinorThe discussion says a higher surface-area-to-volume ratio increases degradation, while the conclusion says a larger volume-to-surface ratio accelerates it. Those ratios move in opposite directions.
“Higher surface area ratio leads to higher degradation of the matrix.”
“In general, the PLGA degradation and the drug release rate can be accelerated by greater hydrophilicity, increase in chemical interactions among the hydrolytic groups, less crystallinity and larger volume to surface ratio of the device.”
The model reverses its boundary and initial-condition labels
MinorEquation (3), called an initial condition, instead specifies concentration at the particle surface for times greater than zero. Equation (2), called a boundary condition, is restricted to time zero.
“The above equation is solved using the following boundary conditions of concentration profile (2) and initial condition (3).”
“(2)∂C(r,t)∂r|r=0,t=0=0 (3)C(r,t)|r=R,t>0=0 where R is the radius of the particle (if spherical).”
Citations
Cites
Biodegradable polymers as biomaterials
Nair, L. S., & Laurencin, C. T. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.017 · Cited by 4,416 · cited 1×
“The basic category of biomaterials used in drug delivery can be broadly classified as (1) synthetic biodegradable polymers, which includes relatively hydrophobic materials such as the α-hydroxy acids (a family that includes poly lactic-coglycolic acid, PLGA), polyanhydrides, and others, and (2) naturally occurring pol…”
BackgroundPolymeric systems for controlled drug release
Uhrich, K. E., Cannizzaro, S. M., Langer, R. S., & Shakesheff, K. M. (1999) · Chemical Reviews · doi:10.1021/cr940351u · Cited by 2,633 · cited 1×
“It is soluble in wide range of common solvents including chlorinated solvents, tetrahydofuran, acetone or ethyl acetate [7,10].”
BackgroundBiodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617 · cited 2×
“This section describes various fabrication techniques of PLGA controlled drug delivery devices [9].”
BackgroundMethodJain, R. A. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00115-0 · Cited by 2,214
Biodegradable nanoparticles for drug delivery and targeting
Hans, M. L., & Lowman, A. M. (2002) · Current Opinion in Solid State and Materials Science · doi:10.1016/s1359-0286(02)00117-1 · Cited by 1,324
Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273 · cited 5×
“PLGA/PEG block copolymers have been processed as diblock (PLGA-PEG) [18,19] or triblock molecules with both ABA (PLGAPEG-PLGA) [20] and BAB (PEG-PLGA-PEG) [21] types.”
BackgroundInfluentialMundargi, R. C., Babu, V. R., Rangaswamy, V., Patel, P., & Aminabhavi, T. M. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.09.013 · Cited by 1,025 · cited 1×
“Additionally, it is possible to tune the overall physical properties of the polymer-drug matrix by controlling the relevant parameters such as polymer molecular weight, ratio of lactide to glycolide and drug concentration to achieve a desired dosage and release interval depending upon the drug type [4–6].”
BackgroundMicro/Nano encapsulation via electrified coaxial liquid jets
Loscertales, I. G., Barrero, A., Guerrero, I., Cortijo, R., Marquez, M., & Gañán-Calvo, A. M. (2002) · Science · doi:10.1126/science.1067595 · Cited by 1,017 · cited 1×
“Additionally, microfluidic devices can incorporate the use of electrostatic forces to control the size and shape of particles for increased tuning of release characteristics [53].”
Dhar, S., Gu, F., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994 · cited 1×
“Various mechanisms of targeted delivery of drugs from diblock nanoparticles have also been reported [18,23,24].”
BackgroundFreitas, S., Merkle, H. P., & Gander, B. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.10.015 · Cited by 923 · cited 1×
“Recently, coaxial capillary flows have become a preferable technique to produce monodispersed micro/nanoparticles with either simple or core-shell structure because of their precise control on mean particle size [50,51].”
Method
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 4,778
Chew, S. A., Arriaga, M. A., & Hinojosa, V. A. (2016) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.35657 · Cited by 61
Roque, L., Castro, P. M., Molpeceres, J., Viana, A. S., Roberto, A., Reis, C. B. S., Rijo, P. M., Tho, I., Sarmento, B. F. C. C., & Reis, C. P. (2018) · European Polymer Journal · doi:10.1016/j.eurpolymj.2018.04.032 · Cited by 61
Porous biomaterial scaffolds for skeletal muscle tissue engineering
Kozan, N. G., Joshi, M., Sicherer, S. T., & Grasman, J. M. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1245897 · Cited by 62
“PLGA is a biocompatible and biodegradable synthetic polymer that has been used in biomedical applications for decades (Makadia and Siegel, 2011).”
BackgroundPediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies
Domingues, C., Jarak, I., Veiga, F., Dourado, M., & Figueiras, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102431 · Cited by 69
“PLGA is an aliphatic polyester polymer that comprises a synthetic copolymer of lactic acid ( α -hydroxy propanoic acid) and glycolic acid (hydroxy acetic acid) with demonstrated potential for drug delivery and tissue engineering scaffolds [192].”
BackgroundIbraheem, D., Iqbal, M., Agusti, G., Fessi, H., & Elaı̈ssari, A. (2014) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2014.01.012 · Cited by 61
Preparation of Drug-Loaded PLGA-PEG Nanoparticles by Membrane-Assisted Nanoprecipitation
Albisa, A., Piacentini, E., Sebastián, V., Arruebo, M., Santamarı́a, J., & Giorno, L. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2146-y · Cited by 60
“formed during 15 days because this period is enough to study the kinetics of the system [2].”
InfluentialAdvances in Materials for Recent Low-Profile Implantable Bioelectronics
Chen, Y., Kim, Y., Tillman, B. W., Yeo, W., & Chun, Y. (2018) · Materials · doi:10.3390/ma11040522 · Cited by 63
Chen, E. M., Quijano, A., Seo, Y.-E., Jackson, C. B., Josowitz, A. D., Noorbakhsh, S. I., Merlettini, A., Sundaram, R. K., Focarete, M. L., Jiang, Z., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.06.024 · Cited by 63
Kłodzińska, S. N., Wan, F., Jumaa, H., et al. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2019.08.006 · Cited by 61
Albumin nanocarriers for pulmonary drug delivery: An attractive approach
Joshi, M., Nagarsenkar, M., & Prabhakar, B. R. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101529 · Cited by 61
Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells
Zhou, G., Latchoumanin, O., Bagdesar, M., Hebbard, L., Duan, W., Liddle, C., George, J., & Qiao, L. (2017) · Theranostics · doi:10.7150/thno.20725 · Cited by 63
Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy
Hao, Y., Chung, C. K., Yu, Z., Veld, R. V. H. I. ‘., OSSENDORP, F. A., ten Dijke, P., & Cruz, L. J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010120 · Cited by 60
“, polylactic acid (PLA), polyglycolic acid (PGA), or their copolymers, such as polyester (PLGA) and polyethylene glycol (PEG)), which can be hydrolyzed enzymatically into nontoxic byproducts in metabolic environments [99].”
BackgroundAlkholief, M. A., Kalam, M. A., Anwer, M. K., & Alshamsan, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040870 · Cited by 65
“, poly D,L-Lactide-co-glycolic Acid, PLGA), on the other hand, have become more preferable to formulation scientists as drug delivery carriers, due to their superior biodegradability and biocompatibility properties [8,9].”
BackgroundEngineering hybrid nanosystems for efficient and targeted delivery against bacterial infections
Elhassan, E., Devnarain, N., Mohammed, M., Govender, T., & Omolo, C. A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.052 · Cited by 61
Extremophile-based biohybrid micromotors for biomedical operations in harsh acidic environments
Zhang, F., Li, Z., Duan, Y., Luan, H., Yin, L., Guo, Z., Chen, C., Xu, M., Gao, W., Fang, R. H., et al. (2022) · Science Advances · doi:10.1126/sciadv.ade6455 · Cited by 63
“Once inside the GI tract, the PLGA nanoparticles provide controlled and sustained drug release through the hydrolytic cleavage of their polyester backbones (54).”
BackgroundAdvanced manufacturing of nanoparticle formulations of drugs and biologics using microfluidics
Shen, Y., Gwak, H., & Han, B. (2023) · The Analyst · doi:10.1039/d3an01739g · Cited by 65
Khan, M. (2024) · Polymers · doi:10.3390/polym16182629 · Cited by 64
Lim, M. P. A., Lee, W., Widjaja, E., et al. (2013) · Biomaterials Science · doi:10.1039/c3bm00175j · Cited by 60
Lim, H. P., Tey, B. T., & Chan, E. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.042 · Cited by 60
Nanomaterials for Cardiac Myocyte Tissue Engineering
Amezcua, R., Shirolkar, A., Fraze, C., & Stout, D. (2016) · Nanomaterials · doi:10.3390/nano6070133 · Cited by 60
“By combining these two materials, PLGA has advantages such as adjustable mechanical properties by controlling its polymer molecular weight, favorable degradation rate, and can be manipulated into any shape and size [28].”
BackgroundPLGA nanoparticles as chlorhexidine-delivery carrier to resin-dentin adhesive interface
Priyadarshini, B. M., Kakran, M., Lu, T. B., Handral, H. K., Dubey, N., & Fawzy, A. (2017) · Dental Materials · doi:10.1016/j.dental.2017.04.015 · Cited by 60
Contact lenses for ophthalmic drug delivery
Hui, A. (2017) · Clinical and Experimental Optometry · doi:10.1111/cxo.12592 · Cited by 60
“It has been studied not only in ocular applications, but also as a means for tissue scaffolds and drug delivery implants in the rest of the body.(38) The material has a high strength and release characteristics that can be tailored through the relative composition of the lactide to glycolide in the final material.”
BackgroundInfluentialIR820‐loaded PLGA nanoparticles for photothermal therapy of triple‐negative breast cancer
Valcourt, D. M., Dang, M. N., & Day, E. S. (2019) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36685 · Cited by 61
Zeeshan, M., Ali, H., Khan, S., Mukhtar, M., Khan, M. I., & Arshad, M. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0415 · Cited by 60
Use of rabbit eyes in pharmacokinetic studies of intraocular drugs
Ahn, S. J., Hong, H. K., Na, Y. M., Park, S. J., Ahn, J., Oh, J., Chung, J. Y., Park, K. H., & Woo, S. J. (2016) · Journal of Visualized Experiments · doi:10.3791/53878 · Cited by 60
Apoptotic and Nonapoptotic Activities of Pterostilbene against Cancer
Chen, R.-J., Kuo, H.-C., Cheng, L.-H., Lee, Y., Chang, W., Wang, B.-J., Wang, Y.-J., & Cheng, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010287 · Cited by 60
“Fabricating devices for drug delivery by using the Poly(lactic-co-glycolic) acid (PLGA), which has been approved in clinical use by the US Food and Drug Administration (FDA), has attracted attentions as a base material for biomedical applications [167,168].”
BackgroundEmerging frontiers in drug release control by core–shell nanofibers: a review
Monfared, M., Taghizadeh, S., Zare-Hoseinabadi, A., et al. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1642912 · Cited by 59
“Makadia and Siegel (2011) are devoted to a comprehensive review of PLGA.”
BackgroundZhou, J., Walker, J. L., Ackermann, R., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01188 · Cited by 59
Drug delivery across the blood-brain barrier for the treatment of pediatric brain tumors – An update
Power, E. A., Rechberger, J. S., Gupta, S. K., Schwartz, J., Daniels, D. J., & Khatua, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114303 · Cited by 63
Targeted Strategy in Lipid-Lowering Therapy
Dayar, E., & Pecháňová, O. (2022) · Biomedicines · doi:10.3390/biomedicines10051090 · Cited by 63
“Among biodegradable polymeric nanoparticles, poly(lactic-co-glycolic acid) (PLGA) which is approved by FDA (for review see [51]) was investigated using different statins.”
BackgroundCore–Shell Type Lipidic and Polymeric Nanocapsules: the Transformative Multifaceted Delivery Systems
Mehandole, A., Walke, N., Mahajan, S., Aalhate, M., Maji, I., Gupta, U., Mehra, N. K., & Singh, P. K. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02504-z · Cited by 63
Recent Development of Nanomaterials for Transdermal Drug Delivery
Leong, M. Y., Kong, Y. L., Burgess, K., Wong, W. F., Sethi, G., & Looi, C. Y. (2023) · Biomedicines · doi:10.3390/biomedicines11041124 · Cited by 61
Depot-Based Delivery Systems for Pro-Angiogenic Peptides: A Review
Hove, A. H. V., & Benoit, D. S. W. (2015) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2015.00102 · Cited by 62
“However, these scaffolds present a unique material compared to the other gels discussed here, in that they have significantly greater structural integrity (Makadia and Siegel, 2011).”
BackgroundInfluentialWang, X., Sng, M. K., Foo, S. E. M., Chong, H. C., Lee, W. L., Tang, M. B. Y., Ng, K. W., Luo, B., Choong, C. S. N., Wong, M. T. C., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.001 · Cited by 61
Yang, K., Park, E., Lee, J. S., Kim, I., Hong, K., Park, K. I., Cho, S., & Yang, H. S. (2015) · Macromolecular Bioscience · doi:10.1002/mabi.201500080 · Cited by 60
Kurniawan, D. W., Jajoriya, A. K., Dhawan, G., Mishra, D., Argemí, J., Bataller, R. A., Storm, G., Mishra, D. P., Prakash, J., & Bansal, R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.004 · Cited by 62
“PLGA is a FDA-approved biodegradable polymer with favorable mechanical properties, biodegradation kinetics, drug compatibility and biocompatibility since PLGA is biologically hydrolyzed to metabolite monomers, lactic acid and glycolic acid [25].”
BackgroundMethodInfluentialNejad, Z. M., Torabinejad, B., Davachi, S. M., Zamanian, A., Garakani, S. S., Najafi, F., & Nezafati, N. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.12.181 · Cited by 59
Park, H., Ha, D.-H., Ha, E., Kim, J. S., Kim, M., & Hwang, S. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11120627 · Cited by 59
“The heat and hydration during the SE process could reduce the Tg of PLGA [55].”
BackgroundLyotropic liquid crystalline phases: Drug delivery and biomedical applications
Chavda, V. P., Dyawanapelly, S., Dawre, S., Ferreira-Faria, I., Bezbaruah, R., Gogoi, N. R., Kolimi, P., Dave, D. J., Paiva‐Santos, A. C., & Vora, L. K. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123546 · Cited by 58
Nanoparticle-polymer composite scaffolds for bone tissue engineering. A review
Chimal, R. Á., Arenas-Alatorre, J. A., & Álvarez-Pérez, M. A. (2024) · European Polymer Journal · doi:10.1016/j.eurpolymj.2024.113093 · Cited by 65
Thermodynamic phase behaviour of indomethacin/PLGA formulations
Prudic, A., Lesniak, A., Ji, Y., & Sadowski, G. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.029 · Cited by 58
Ghasemian, E., Vatanara, A., Najafabadi, A. R., Rouini, M. R., Gilani, K., & Darabi, M. (2013) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/2008-2231-21-68 · Cited by 58
Controlled and Sequential Delivery of Fluorophores from 3D Printed Alginate-PLGA Tubes
Do, A., Akkouch, A., Green, B. J., Ozbolat, I. T., Debabneh, A., Geary, S. M., & Salem, A. K. (2016) · Annals of Biomedical Engineering · doi:10.1007/s10439-016-1648-9 · Cited by 58
Design of Mucoadhesive PLGA Microparticles for Ocular Drug Delivery
Ding, D., Kundukad, B., Somasundar, A., Vijayan, S., Khan, S. A., & Doyle, P. S. (2018) · ACS Applied Bio Materials · doi:10.1021/acsabm.8b00041 · Cited by 58
Biodegradable polymers for modern vaccine development
Bose, R. J., Kim, M., Chang, J. H., Paulmurugan, R., Moon, J. J., Koh, W., Lee, S.-H., & Park, H. (2019) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2019.04.044 · Cited by 58
Materials promoting viral gene delivery
Kaygisiz, K., & Synatschke, C. V. (2020) · Biomaterials Science · doi:10.1039/d0bm01367f · Cited by 57
Cesari, A. B., Loureiro, M. V., Vale, M., Yslas, E. I., Dardanelli, M. S., & Marques, A. C. (2019) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2019.135548 · Cited by 57
PLGA Based Nanospheres as a Potent Macrophage-Specific Drug Delivery System
Boltnarova, B., Kubackova, J., Škoda, J., Štefela, A., Smékalová, M., Svačinová, P., Pávková, I., Dittrich, M., Scherman, D., Zbytovská, J., et al. (2021) · Nanomaterials · doi:10.3390/nano11030749 · Cited by 58
“The drug release profile is influenced by PLGA degradation rate, initial molar mass, fabrication method or pH of environment and the nature of PLGA-drug interactions [19].”
BackgroundYang, F., Cabe, M. H., Nowak, H. A., & Langert, K. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010095 · Cited by 58
“Controlled, local release from PLGA nanoparticles allows therapeutic doses to be achieved in the tissue of interest while minimizing systemic side effects and toxicity [29,30].”
BackgroundGujjari, L., Kalani, H., Pindiprolu, S. K. S. S., Arakareddy, B. P., & Yadagiri, G. (2022) · Parasite Epidemiology and Control · doi:10.1016/j.parepi.2022.e00244 · Cited by 62
Polymer-based drug delivery systems for anticancer drugs: A systematic review
Salari, N., Faraji, F., Torghabeh, F. M., Faraji, F., Mansouri, K., Abam, F., Shohaimi, S., Akbari, H., & Mohammadi, M. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100605 · Cited by 65
Puricelli, C., Gigliotti, C. L., Stoppa, I., Sacchetti, S., Pantham, D., Scomparin, A., Rolla, R., Pizzimenti, S., Dianzani, U., Boggio, E. M., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061772 · Cited by 62
“PLGA is an FDA-approved, biodegradable, and biocompatible synthetic polymer widely used to develop nano-sized drug delivery carriers [17].”
BackgroundMoshkbid, E., Cree, D. E., Bradford, L., & Zhang, W. (2024) · Journal of Composites Science · doi:10.3390/jcs8090342 · Cited by 70
Polylactic acid (PLA) biomedical foams for tissue engineering
Mohammadi, M. S., Bureau, M., & Nazhat, S. N. (2014) · Elsevier eBooks · doi:10.1533/9780857097033.2.313 · Cited by 58
Bare and Sterically Stabilized PLGA Nanoparticles for the Stabilization of Pickering Emulsions
Albert, C., Huang, N., Tsapis, N., et al. (2018) · Langmuir · doi:10.1021/acs.langmuir.8b02558 · Cited by 57
Preferential uptake of chitosan-coated PLGA nanoparticles by primary human antigen presenting cells
Durán, V., Yasar, H., Becker, J., Thiyagarajan, D., Loretz, B., Kalinke, U., & Lehr, C. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.102073 · Cited by 57
Ramalho, M. J., Loureiro, J. A., Coelho, M. A. N., & Pereira, M. D. C. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11080401 · Cited by 62
“Also, it can be challenging to entrap hydrophilic drugs, since those exhibit a high partition into the aqueous phase during NPs preparation [6].”
BackgroundXu, K., An, N., Zhang, H., Zhang, Q., Zhang, K., Hu, X., Wu, Y., Wu, F., Xiao, J., Zhang, H., et al. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101405 · Cited by 58
Birolini, G., Valenza, M., Ottonelli, I., Passoni, A., Favagrossa, M., Duskey, J. T., Bombaci, M., Vandelli, M. A., Colombo, L., Bagnati, R., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.051 · Cited by 57
Reinbold, J., Uhde, A.-K., Müller, I., Weindl, T., Geis-Gerstorfer, J., Schlensak, C., Wendel, H.-P., & Krajewski, S. (2017) · Molecules · doi:10.3390/molecules22091570 · Cited by 55
“Exposure to water might cause swelling and the change of shape in PLGA over time [29].”
BackgroundParumasivam, T., Leung, S. S. Y., Quan, D. H., Triccas, J. A., Britton, W. J., & Chan, H. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.03.024 · Cited by 56
A Current Overview of Scaffold-Based Bone Regeneration Strategies with Dental Stem Cells
Ercal, P., & Peközer, G. G. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_505 · Cited by 57
The Stabilizing Excipients in Dry State Therapeutic Phage Formulations
Zhang, Y., Zhang, H., & Ghosh, D. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01673-5 · Cited by 57
Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies
Hasanzadeh, A., Alamdaran, M., Ahmadi, S., Nourizadeh, H., Bagherzadeh, M. A., Jahromi, M. A. M., Simon, P. D., Karimi, M., & Hamblin, M. R. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.036 · Cited by 59
“The FDA has approved liposomal nanomaterials, such as DaunoXome, Abelcet, and Caelyxor, or polymer NPs such as Macugen [268] to treat various diseases.”
InfluentialDesign principles for bacteria-responsive antimicrobial nanomaterials
Quek, J. Y., Uroro, E. O., Goswami, N., & Vasilev, K. A. (2021) · Materials Today Chemistry · doi:10.1016/j.mtchem.2021.100606 · Cited by 56
van der Kooij, R. S., Steendam, R., Frijlink, H. W., & Hinrichs, W. L. J. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.11.007 · Cited by 60
Prakash, N., Kim, J., Jeon, J., Kim, S., Arai, Y., Bello, A. B., Park, H., & Lee, S.-H. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00371-0 · Cited by 56
“The PGA component imparts degradable properties, whereas the PLA component provides improved cell adhesion, which makes PLGA extremely useful for regulating various cellular activities [184].”
BackgroundNanoparticles-assisted Wound Healing: A Review
Hamed, S., Azooz, E., & Al-Mulla, E. (2023) · Nano Biomedicine and Engineering · doi:10.26599/nbe.2023.9290039 · Cited by 35
Formulation and characterization of microspheres loaded with imatinib for sustained delivery
Ramazani, F., Chen, W., van Nostrum, C. F., Storm, G., Kiessling, F. M., Lammers, T., Hennink, W. E., & Kok, R. J. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.01.043 · Cited by 59
Yalcın, T. E., Ilbasmiş-Tamer, S., İbişoğlu, B., et al. (2017) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2017.1357733 · Cited by 56
“It is observed that the biodegradation rate of the PLGA copolymers depends on not only the molar ratio of the lactic and glycolic acids in the polymer chain but also the molecular weight of the polymer (Makadia and Siegel 2011).”
BackgroundHydrolytic Degradation of PCL–PLLA Semi-IPNs Exhibiting Rapid, Tunable Degradation
Woodard, L. N., & Grunlan, M. A. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01135 · Cited by 55
Kefayat, A., & Vaezifar, S. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.06.055 · Cited by 56
Beckers, S. J., Staal, A. H. J., Rosenauer, C., et al. (2021) · Advanced Science · doi:10.1002/advs.202100067 · Cited by 55
Chachlioutaki, K., Karavasili, C., Adamoudi, E., Bouropoulos, N., Tzetzis, D., Bakopoulou, A., & Fatouros, D. G. (2022) · Biomaterials Advances · doi:10.1016/j.msec.2022.112723 · Cited by 57
Exploring the potential of phytochemicals and nanomaterial: A boon to antimicrobial treatment
Yadav, H., Mahalvar, A., Pradhan, M., Yadav, D. K., Sahu, K. K., & Yadav, R. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100151 · Cited by 63
Li, J., Leung, S. S. Y., Chung, Y. L., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.03.044 · Cited by 55
Biffi, S., Voltan, R., Rampazzo, E., Prodi, L., Zauli, G., & Secchiero, P. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1071791 · Cited by 55
“Organic nanoparticles Polymer-based nanoformulations Diameter from 5 to 300 nm; controlled release property; surface functionalization and bioconjugation Drug delivery; bioimaging [25-31]”
BackgroundVivek, R., Thangam, R., Kumar, S. R., Rejeeth, C., Sivasubramanian, S., Vincent, S., Gopi, D., & Kannan, S. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b11103 · Cited by 57
Freire, M. O., Devaraj, A., Young, A., Navarro, J. B., Downey, J. S., Chen, C., Bakaletz, L. O., Zadeh, H. H., & Goodman, S. D. (2017) · Molecular Oral Microbiology · doi:10.1111/omi.12155 · Cited by 55
“…including the ratio of glycolic to lactic acid, crystallinity, average molecular weight of the polymer, type of drug encapsulated, and other environmental factors, and therefore the rate of release of the encapsulated molecule can range from a few days to several weeks (Makadia & Siegel, 2011).”
BackgroundGuan, X., Gao, M., Xu, H., Zhang, C., Liu, H.-Y., Lv, L., Deng, S., Gao, D., & Tian, Y. (2016) · Drug Delivery · doi:10.1080/10717544.2016.1176087 · Cited by 55
“Meanwhile, QT-loaded NPs can target to liver by controlling the particle size, surface charge and carrier materials specific identification to liver (Truong et al., 2015), and gradually degraded to release drugs after phagocytosed by liver cancer cells (Makadia & Siegel, 2011).”
BackgroundLi, Q., Wen, Y., You, X., Zhang, F., Shah, V., Chen, X., Tong, D., Wei, X., Yin, L., Wu, J., et al. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01016d · Cited by 56
Fernández‐Sánchez, L., Bravo‐Osuna, I., Lax, P., Arranz-Romera, A., Maneu, V., Esteban-Pérez, S., Pinilla, I., Puebla-González, M. D. M., Herrero‐Vanrell, R., & Cuenca, N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177998 · Cited by 59
Biopolymer-Based Nanoparticles for Cystic Fibrosis Lung Gene Therapy Studies
Fernández, E. F., Santos-Carballal, B., Santi, C. D., Ramsey, J. M., MacLoughlin, R. J., Cryan, S., & Greene, C. M. (2018) · Materials · doi:10.3390/ma11010122 · Cited by 55
“, a copolymer whose composition is 50% lactide and 50% glycolide) is the most widely used copolymer, with the fastest biodegradation rate, which degrades in about 50 to 60 days [19].”
BackgroundZaman, R. U., Mulla, N. S., Gomes, K. B., D’Souza, C., Murnane, K. S., & D’Souza, M. J. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.07.043 · Cited by 55
“We focused our efforts on using PLGA and BSA for our nanoparticle polymers because they are biocompatible, biodegradable, and are approved by the US Food and Drug Administration (FDA) (Makadia and Siegel, 2011; Jalil and Nixon, 1990; Jain, 2000; Ma et al., 2016; Wang et al., 2016; Oettinger et al., 2007).”
Anderski, J., Mahlert, L., Sun, J., et al. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.12.040 · Cited by 55
Verteporfin-Loaded Polymeric Microparticles for Intratumoral Treatment of Brain Cancer
Shah, S. R., Kim, J., Schiapparelli, P. V., Vazquez-Ramos, C. A., Martínez-Gutiérrez, J. C., Ruiz‐Valls, A., Inman, K. W., Shamul, J. G., Green, J. J., & Quiñones‐Hinojosa, A. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00959 · Cited by 54
Microfluidics-Assisted Size Tuning and Biological Evaluation of PLGA Particles
Operti, M. C., Dölen, Y., Keulen, J., van Dinther, E. A. W., Figdor, C. G., & Tagit, O. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110590 · Cited by 53
“The conventional production techniques based on emulsion solvent diffusion, emulsion solvent evaporation, and nanoprecipitation are suitable for the production of sub-micron and micron-size PLGA particles [7,8]; however, these methods lack the precision and full control over the particle size and uniformity particular…”
BackgroundMethodÖztürk, A. A., Namlı, İ., Güleç, K., & Kıyan, H. T. (2020) · Microvascular Research · doi:10.1016/j.mvr.2020.103991 · Cited by 55
Prabhuraj, R. S., Bomb, K., Srivastava, R., & Bandyopadhyaya, R. (2020) · Journal of Polymer Research · doi:10.1007/s10965-020-02092-7 · Cited by 55
Injectables and Depots to Prolong Drug Action of Proteins and Peptides
Ibeanu, N., Egbu, R., Onyekuru, L., Javaheri, H., Khaw, P. T., Williams, G. R., Brocchini, S., & Awwad, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100999 · Cited by 56
“PLGA is one of the most commonly used polymers and is a good exemplar that many polymer properties, such as biodegradability, crystallinity and polymer hydrophilicity dependent monomer ratios and polymer molecular weight characteristic, will influence drug loading and release properties [112,113].”
BackgroundAkbari, E., Mousazadeh, H., Sabet, Z., Fattahi, T., Dehnad, A., Akbarzadeh, A., & Alizadeh, E. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102294 · Cited by 54
Sabuj, M. Z. R., & Islam, N. (2021) · Nanoscale Advances · doi:10.1039/d1na00205h · Cited by 56
Onesto, V., Natale, C. D., Profeta, M., Netti, P. A., & Vecchione, R. (2020) · Progress in Biomaterials · doi:10.1007/s40204-020-00143-2 · Cited by 54
Formulation of tunable size PLGA-PEG nanoparticles for drug delivery using microfluidic technology
Mares, A. G., Pacassoni, G., Samitier, J., Pujals, S., & Albertazzi, L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251821 · Cited by 53
“PLGA breaks down to the lactic and glycolic acids, ensuring the biocompatibility and biodegradability required for safe use in humans [27, 28].”
BackgroundManivasagan, P., Kim, J., & Jang, E. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214701 · Cited by 55
Use of acidic nanoparticles to rescue macrophage lysosomal dysfunction in atherosclerosis
Zhang, X., Misra, S. K., Moitra, P., Zhang, X., Jeong, S., Stitham, J., Rodríguez-Vélez, A., Park, A. C., Yeh, Y., Gillanders, W. E., et al. (2022) · Autophagy · doi:10.1080/15548627.2022.2108252 · Cited by 65
Lee, J., Kim, D., Park, S., Baek, S., Jung, J., Kim, T. P., & Han, D. K. (2022) · Advanced Science · doi:10.1002/advs.202205336 · Cited by 55
Nanotechnology-Based Solutions for Antibiofouling Applications: An Overview
Sinha, S., Kumar, R., Anand, J., Gupta, R., Gupta, A., Pant, K., Dohare, S., Tiwari, P., Kesari, K. K., Krishnan, S., et al. (2023) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c01539 · Cited by 57
Nanoparticles in Periodontitis Therapy: A Review of the Current Situation
Wang, D., Li, Q., Xiao, C., Wang, H., & Dong, S. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s465089 · Cited by 64
“142,143 BAR (SspB Adherence Region) is a region of streptococcal antigens that suppresses P. gingivalis or Streptococcus gordonii ( S. gordonii ) interaction and biofilm formation.”
BackgroundHeuristic modeling of macromolecule release from PLGA microspheres
Mendyk, A., Szlęk, J., Jachowicz, R., et al. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s53364 · Cited by 54
“It also has the ability to modify the drug dissolution profile for controlled-release formulations.(1) Moreover, the drug protective properties of PLGA were found to be suitable for unstable active pharmaceutical ingredients (APIs).”
BackgroundMethodResult
Metadata
- Authors
- Makadia, H. K., & Siegel, S. J.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Siegel, Steven J.
- Venue
- Polymers
- Publisher
- MDPI AG
- Published
- 2011-08-26
- Volume
- 3
- Issue
- 3
- Pages
- 1377-1397
- ISSN
- 2073-4360 (ISSN-L)
- PMC
- PMC3347861
- OpenAlex
- W2087032263
- Semantic Scholar
- 3649c008437b4a4a59c67419af5d7fe7bf3594a7
- Cited by
- 4,816
- References
- 98
- Citations by year
- 2026: 490 · 2025: 477 · 2024: 387 · 2023: 394 · 2022: 419 · 2021: 406 · 2020: 435 · 2019: 412 · 2018: 373 · 2017: 305 · 2016: 266 · 2015: 212 · 2014: 138 · 2013: 75 · 2012: 24
- FWCI
- 46.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Polymers (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of Mental Health (R01MH074672)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › biodegradable polymer synthesis and properties
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- poly(lactic-co-glycolic acid), PLGA, controlled drug delivery, biodegradable polymers, biocompatibility, drug release, polymer degradation, tissue engineering, small molecule drugs, protein delivery, macromolecule delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review